Cannabis Use Disorder (CUD)
A DSM-5 diagnosis characterized by problematic cannabis use leading to clinically significant impairment or distress, with at least 2 of 11 criteria met within a 12-month period.
In Depth
CUD affects approximately 9% of people who ever use cannabis and 17% of those who begin in adolescence. Risk factors include early onset of use, daily use, high-potency products, and genetic predisposition. Withdrawal symptoms (irritability, sleep disturbance, appetite changes, anxiety) occur in approximately 50% of daily users who stop. No FDA-approved pharmacotherapy exists for CUD. Cognitive behavioral therapy (CBT) and motivational enhancement therapy (MET) have the strongest evidence base.
Related Terms
Further Reading
More in Clinical
Dravet Syndrome
A severe, treatment-resistant form of childhood epilepsy characterized by prolonged seizures, often triggered by fever, beginning in the first year of life.
Lennox-Gastaut Syndrome (LGS)
A severe form of childhood-onset epilepsy characterized by multiple seizure types, slow spike-wave EEG pattern, and cognitive impairment.
Epidiolex
The FDA-approved pharmaceutical formulation of purified cannabidiol (CBD), manufactured by GW Pharmaceuticals (now Jazz Pharmaceuticals). Approved in 2018 for Dravet syndrome and Lennox-Gastaut syndrome.
Dronabinol (Marinol)
A synthetic form of THC (Δ9-tetrahydrocannabinol) approved by the FDA for chemotherapy-induced nausea/vomiting and AIDS-related anorexia.
Nabilone (Cesamet)
A synthetic cannabinoid analogue of THC approved for chemotherapy-induced nausea and vomiting. More potent than dronabinol.